Inhaled insulin from conception to...success?

/ 3218 Views

Demonstrating “healthcare value” is key to avoiding another Exubera

25/11/2008

Pfizer’s Exubera failure need not be the final nail in the coffin for inhaled biopharmaceuticals as long as developers focus on proving “healthcare value” and addressing payer needs, according to B...

Small step for MannKind resurrects inhaled insulin

17/09/2008

MannKind’s inhaled insulin treatment, Technosphere, has met its study goal in the first of three Phase III trials, leading to Pfizer transferring its remaining Exubera patients to the treatment.

Exubera hangover hits West Tech group

07/08/2008

The discontinuation of Pfizer’s inhalable diabetes treatment Exubera (insulin human [rDNA origin) once again hurt West’s Tech services group. The division, which was responsible for the manufacture...

West looks ahead to healthier 2008

20/05/2008

Packaging component manufacturer West Pharmaceutical Services has shrugged off the after-effects of a difficult 2007 with an increase in revenues in the first quarter of 2008 that came ahead of ana...

Pfizer closes plant earmarked for Exubera

19/05/2008

Pfizer is planning to close its Terre Haute, Indiana manufacturing facility which had received $300m of investment to prepare it for Exubera production.

Pfizer to continue with manufacturing cuts

22/04/2008

Pfizer's decision to drop the inhaled diabetes drug Exubera has left the firm with considerable overcapacity. Mr D'Amelio specified that two of the insulin production facilities that the firm had s...

MannKind stumbles in fallout from Exubera

14/04/2008

MannKind has suspended its search for a potential partner for its inhaled insulin product Technosphere in the wake of the news of Exubera's possible cancer risk.

Lung cancer warning a death knell for inhaled insulin?

10/04/2008

Pfizer has updated the US product labeling of its inhaled insulin treatment Exubera to include a warning of increased risk of lung cancer among those using it.

Alkermes takes AIR Insulin blow with redundancies, facility closure

20/03/2008

US-based drug delivery specialist Alkermes is cutting its losses following Eli Lilly's decision to scrap the companies' joint development programme for inhaled insulin.

Lilly declines to inhale with AIR Insulin programme

11/03/2008

The prospects for a viable market in inhaled insulin therapies were looking markedly thinner this week after Eli Lilly pulled the plug on its joint development programme with drug delivery speciali...

Pfizer expands in inhaled drugs as Nektar cuts back

13/02/2008

Pfizer's announcement of plans to create a new €130m inhaled medicines unit at its facility in Amboise, France suggests that the firm is still intent on investing in inhalation technology, despite ...

Pfizer reveals latest Exubera casualties

29/01/2008

660 Pfizer employees are the latest casualties of the drug giant's failed bid to capture the diabetes market with its once-touted blockbuster, Exubera.

Novo drops inhaled insulin plans in post-Exubera fallout

15/01/2008

Mere months after Pfizer's high profile exit from the inhaled insulin market in the wake of Exubera's much publicised market failure, Novo Nordisk announced late last night that it, too, has decide...

Pfizer, Nektar agreement not so sweet after all?

14/11/2007

Pfizer yesterday announced a multi-million dollar pay-off to ex-partner Nektar Therapeutics, but the details of the deal reveal not only Nektar's concerns for its future, but also that Pfizer is st...

West unscathed by Exubera shot - for now

08/11/2007

West Pharmaceutical Services, one of the two firms responsible for manufacturing Pfizer's failed Exubera device, recently turned in its third quarter financials, so far avoiding any major dent from...